Loading clinical trials...
Loading clinical trials...
TH-112: Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle Aspirate
Needle biopsy samples are routinely collected to evaluate cytomorphology, immunohistochemical markers and for mutational analysis. With regular use of immunotheraputic interventions, needle biospy has become more frequent and requires bigger samples for an increasing battery of tests. There has been no clear consensus on which biopsy needle yields the best biopsy sample. It is unclear if large 19g needle offers better yield than a 22 g needle. Although previous studies comparing 21, 22 and 19g needles have suggested that larger needles yield larger biopsy sizes, conflictng studies have shown that larger biopsies lead to bloodier samples with potentially smaller fragments of tissue, offering no improvement in diagnostic, yield, adequacy or sample size. This study compares biopsy samples collected using 19g and 22g needles from patients of non small cell lung cancer (NSCLC) scheduled to undergo endobronchial ultrasound (EBUS) and transbroncial needle aspiration (TBNA).
Primary Objective To compare the diagnostic yield of 22g and 19g EBUS transbronchial needle aspirate (TBNA) Secondary Objectives 1. To compare the sample adequacy of 22g and 19g EBUS TBNA 2. To compare the sample quality of 22g and 19 g EBUS TBNA
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Start Date
May 15, 2018
Primary Completion Date
June 8, 2020
Completion Date
June 8, 2020
Last Updated
October 8, 2020
40
ACTUAL participants
Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)
PROCEDURE
Lead Sponsor
Fox Chase Cancer Center
NCT07485114
NCT06066138
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions